Esperion Therapeutics (ESPR) Treasury Shares (2012 - 2026)

Esperion Therapeutics' Treasury Shares history runs 7 years deep, the most recent figure standing at $55.0 million for Q1 2026.

• Quarterly Treasury Shares changed 0.0% year-over-year to $55.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $55.0 million, changed 0.0% from the prior year.
• Treasury Shares was $55.0 million for Q1 2026 at Esperion Therapeutics, roughly flat from $55.0 million in the prior quarter.
• Across five years, Treasury Shares topped out at $10.9 million in Q1 2026 and bottomed at $160275.0 in Q4 2023.
• A 5-year average of $4.5 million and a median of $3.2 million in 2023 frame the typical range for Treasury Shares.
• Peak annual rise in Treasury Shares reached 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
• Esperion Therapeutics' Treasury Shares stood at $55.0 million in 2022, then changed by 0.0% to $55.0 million in 2023, then changed by 0.0% to $55.0 million in 2024, then changed by 0.0% to $55.0 million in 2025, then changed by 0.0% to $55.0 million in 2026.
• Business Quant data shows ESPR's Treasury Shares at $55.0 million in Q1 2026, $55.0 million in Q4 2025, and $55.0 million in Q3 2025.